Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.49 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Teva Pharmaceutical Industries Stock Performance
Shares of TEVA stock opened at $13.98 on Monday. Teva Pharmaceutical Industries has a 12 month low of $7.09 and a 12 month high of $14.47. The stock has a market cap of $15.67 billion, a PE ratio of -29.74, a price-to-earnings-growth ratio of 1.67 and a beta of 1.04. The company’s fifty day moving average price is $13.61 and its 200-day moving average price is $11.61. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23.
Insider Activity
In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the sale, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the transaction, the chief executive officer now owns 87,125 shares in the company, valued at approximately $1,145,693.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now owns 1 shares of the company’s stock, valued at $13.05. The disclosure for this sale can be found here. Insiders sold 358,972 shares of company stock valued at $4,739,820 over the last three months. Insiders own 0.55% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on TEVA
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Read More
- Five stocks we like better than Teva Pharmaceutical Industries
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 4/29 – 5/3
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Are Dividend Achievers? An Introduction
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.